CFZ 533

Drug Profile

CFZ 533

Alternative Names: CFZ533; OM11-62-MF

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graves' disease; Myasthenia gravis; Sjogren's syndrome
  • Phase I/II Renal transplant rejection
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 21 Mar 2017 Novartis Pharmaceuticals completes a phase I trial in Rheumatoid arthritis in USA and Taiwan (NCT02089087)
  • 11 Nov 2016 Phase I development is ongoing for Rheumatoid arthritis in USA (IV, SC)
  • 11 Nov 2016 Interim pharmacodynamics data from a phase I trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top